[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pneumonia-in-children\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pneumonia-in-children":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,74,109],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100639221","bubble-cpap-team-based-care-strategy-feasibility-trial-100639221",false,"NCT07620054","Bubble CPAP Team-Based Care Strategy Feasibility Trial","Feasibility Trial of a Bubble Continuous Positive Airway Pressure Team-Based Care Strategy in Pakistan","Inclusion Criteria:\n\nPediatric participants:\n\n* Provision of signed and dated informed consent form by legal guardian (as determined by local policies and laws)\n* Stated willingness (by guardian) to comply with all study procedures and availability for the duration of the study\n* Presentation to the Emergency Department with cough or difficulty breathing (as documented in triage notes)\n* Meeting the World Health Organization definition for severe pneumonia: Exhibiting severe respiratory distress (clinical respiratory score of at least 8) OR Exhibiting hypoxemia (SpO2\\\u003C90%) OR Exhibiting a general danger sign (Vomiting everything (as reported by child's caregiver), Inability to feed (as reported by child's caregiver), Seizure\u002Fconvulsion (as documented in medical chart or reported by child's caregiver), Reduced level of consciousness (as assessed at screening)\n* In addition, exhibiting either:\n* Severe respiratory distress (clinical respiratory score of at least 8)\n* Hypoxemia (SpO2\\\u003C90%)\n\nPhysicians and nurses:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, over 18 years of age\n* Directly cared for any child receiving bCPAP therapy during the post-implementation period of the study\n\nCaregivers:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, any age\n* Primary caregiver at bedside of a child enrolled in the post-implementation period of our study.\n\nExclusion Criteria:\n\nPediatric participants:\n\n* Known congenital heart disease\n* Asthma\n* Upper airway obstruction\n* Tracheostomy\n\nPhysicians and nurses:\n\n* Temporarily rotating through the department, ward, or unit\n\nCaregivers:\n\n* Does not speak Urdu or English fluently","ALL","1 Month","59 Months",{"count":20,"type":21},95,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this pre\u002Fpost, effectiveness-implementation feasibility trial is to learn if a larger, multisite trial of a bubble continuous positive airway pressure (bCPAP) team-based care strategy is feasible in children with severe pneumonia. The main questions it aims to answer are:\n\nIs a future, larger, multisite trial of a bCPAP team-based care strategy feasible? Is the bCPAP team-based care strategy feasible and acceptable to clinicians and caregivers?",[27],"Pneumonia in Children",[29,30,31],"Bubble continuous positive airway pressure","Pneumonia","CPAP","NOT_YET_RECRUITING","2026-05-20",{"date":35,"type":36},"2026-06-02","ACTUAL",{"date":38,"type":21},"2028-04",{"date":40,"type":21},"2029-03",{"name":42,"class":43},"Yale University","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100639835","effects-of-balloon-blowing-therapy-and-bubble-pep-on-oxygen-saturation-dyspnea-and-enjoyment-in-pediatric-pneumonia-100639835","NCT07578870","Effects of Balloon Blowing Therapy and Bubble PEP on Oxygen Saturation, Dyspnea, and Enjoyment in Pediatric Pneumonia","Comparative Effects of Balloon Blowing Therapy and Bubble PEP on Oxygen Saturation, Dyspnea, and Perceived Enjoyment in Children With Pneumonia","Inclusion Criteria:\n\n* Children aged 6 to 12 years\n* Medically stable and cleared to perform breathing exercises\n* Both genders will be included\n* Presence of dyspnea according to the patient's statement\n* Peripheral oxygen saturation (SpO2) \\\u003C94%\n\nExclusion Criteria:\n\n* Children who are critically ill patients on bi-pep or a ventilator, as well as patients who were intubated and uncooperative\n* Children with any oral surgery\n* Participants were excluded from the study, if they had any contraindication to the use PEP therapy (severe haemoptysis)\n* Refusal to participate or inability to complete full sessions","6 Years","12 Years",{"count":55,"type":21},40,[24],"Pneumonia is a major cause of illness and death in children, leading to breathing difficulties and reduced oxygen levels due to impaired gas exchange. Non-pharmacological techniques like balloon blowing and Bubble PEP are simple, engaging methods used to improve respiratory function.\n\nThis randomized clinical trial will compare the effects of Balloon Blowing Therapy and Bubble PEP on oxygen saturation, dyspnea, and enjoyment in 40 children with pediatric pneumonia over one week.",[27],[30,60,61,62],"Balloon Blowing Therapy","Bubble PEP","Oxygen saturation","RECRUITING","2026-05-05",{"date":66,"type":36},"2026-05-11",{"date":68,"type":36},"2026-04-14",{"date":70,"type":21},"2026-06-05",{"name":72,"class":43},"Riphah International University",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":73},"100623675","assessing-role-of-probiotics-in-children-aged-6-36-months-treated-for-pneumonia-100623675","NCT07399717","Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia","Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia at Phu Tho Provincial Obstetrics and Pediatrics Hospitals Within 2026-2027","Inclusion Criteria:\n\n* Children (male\u002Ffemale) aged 6-36 months diagnosed and hospitalized for treatment for pneumonia.\n* Parents or guradians of the children agree to participate in the study, explain, and sign the research consent form.\n\nExclusion Criteria:\n\n* Children who need ventilator support.\n* Children who have had rhinoplasty surgery, nasal ulcers, nasal polyps or any nasal deformity that affects the use of the study product.\n* Children who get transferred or leave the treatment unit (not for professional reasons).\n* Children who have experienced congenital immunodeficiency or infectious disease (eg, HIV).\n* Children who are concurrently participating in another clinical trial or participated in a clinical trial within 30 days before selection.\n* Children who are under long-term medication (more than 7 consecutive days) within 30 days before selection.\n* Children with allergy or hypersensitivity to any ingredient of the study product.","6 Months","36 Months",{"count":84,"type":21},330,[24],"The main questions this study aims to answer are:\n\n* Does using probiotic nasal spray (LiveSpo Navax containing Bacillus subtilis and Bacillus clausii, 1x10\\^9 CFU\u002FmL), with or without oral probiotics (LiveSpo Pregmom containing Bacillus subtilis, Bacillus clausii, and Bacillus coagulans, 3x10\\^9 CFU\u002F5 mL), help children recover better from pneumonia when added to standard medical treatment?\n* Does using these adjunctive probiotics support reduce the recurrence of respiratory and gastrointestinal symptoms after hospital discharge? Researchers will compare three groups of children to see whether probiotic nasal spray alone or probiotic nasal spray combined with oral probiotics works better than placebo.\n\nAll participants will receive standard medical treatment for pneumonia. In addition, they will be randomly assigned to one of three study groups to receive adjunctive probiotic support in 2 months:\n\n* Control group: receives a saline nasal-throat spray (0.9% NaCl) and oral placebo liquid (RO water).\n* Nasal probiotic group: receives a probiotic LiveSpo® Navax nasal-throat spray and oral placebo liquid (RO water).\n* Nasal plus oral probiotic group: receives a probiotic LiveSpo® Navax nasal-throat spray plus LiveSpo® Preg-Mom oral probiotic suspension.\n\nParticipants will:\n\n* Use a nasal-throat spray three times a day.\n* Take an oral liquid twice daily.\n* Start using the study products during their hospital stay and continue for 8 weeks (2 months) from admission.\n* Be followed by the study team during hospitalization and at Day 30 and Day 60 after admission. The probiotic and placebo products look, smell, and taste the same so that neither the parents nor the study staff know which product each child receives.",[30,27],[89,90,91,92,93,94,95,96,97,98],"Acute respiratory infection","Adjunctive Treatment","Prevention","Nasal-oropharyngeal","Probiotic spray","Oral probiotic suspension","Bacillus spores","Children","Respiratory viruses","Bacterial co-infection","2026-02-03",{"date":101,"type":36},"2026-02-10",{"date":103,"type":21},"2026-01-26",{"date":105,"type":21},"2027-12-30",{"name":107,"class":108},"Anabio R&D","INDUSTRY",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":18,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":121,"conditions":122,"keywords":127,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":73},"100578909","phase-4-opportunistic-pneumococcal-immunisation-trial-in-malnutrition-100578909","NCT06817421","Opportunistic Pneumococcal Immunisation Trial in MALnutrition","Immunogenicity of Opportunistic Pneumococcal Conjugate Vaccination (Pneumosil®) Versus Control (Typhoid Conjugate Vaccine, Typbar TCV®) in Children Aged 6-59 Months Hospitalised With Severe Acute Malnutrition: a Single-centre, Double-blind, Randomised Controlled Trial in Timor-Leste","OPTIMAL","Inclusion Criteria:\n\n1. Aged 6-59 months at the time of hospitalisation\n2. Hospitalised with severe acute malnutrition (SAM, defined as any one of a, b, or c):\n\n   1. weight-for-length\u002Fheight z-score \\\u003C-3; or\n   2. middle upper arm circumference \\\u003C11.5cm; or\n   3. bilateral pitting pedal oedema unexplained by other causes\n3. Parent\u002Fcarer is willing for their child to participate in the study and has provided written informed consent\n4. Parent\u002Fcarer is willing to comply with all study procedures outlined in the protocol, including specimen collection, for the duration of the study\n\nExclusion Criteria:\n\n1. Known history of allergy or hypersensitivity to any component of either study vaccine, including diphtheria toxoid, or a history of anaphylactic shock.\n2. Treatment with another investigational drug or other intervention in the 30 days prior to randomisation, or ongoing participation in another clinical trial.\n3. Suspected primary or secondary immunodeficiency or prolonged administration (\\>14 days) of an immune modifying drug (including oral glucocorticoids) in the past 3 months.\n4. Known terminal illness expected to result in death within 6 months.\n5. Participants who, in the opinion of the site Principal Investigator, are unable to comply with the study protocol, including scheduled visits, assessments, and any other protocol-required procedures.\n6. Previously enrolled in this trial.",{"count":118,"type":21},214,[120],"PHASE4","The goal of the OPTIMAL clinical trial is to learn if a dose of a pneumococcal conjugate vaccine (PCV) generates a good immune response in young children who are in hospital with severe acute malnutrition.\n\nResearchers will compare an intervention group who get a dose of a PCV (Pneumosil) to a control group who get a dose of a Typhoid conjugate vaccine (Typbar TCV). To ensure all participants receive timely potential benefits, at 3 months participants in the intervention group with receive a dose of Typbar TCV, and those in the conrol group will receive a dose of Pneumosil.\n\nParticipants will be visited 4 times at their homes over six months after vaccination, with a phone review at 12 months after vaccination.",[123,124,125,126,27],"Severe Acute Malnutrition in Childhood","Pneumococcal Disease","Pneumococcal Vaccines","Pneumococcal Infection",[128,129,130,131,132,133,30],"Pneumococcal","Severe Acute Malnutrition in childhood","Pneumococcal vaccine","Pneumosil","Pneumococcal disease","Pneumococcal infection","2025-12-10",{"date":136,"type":36},"2025-12-18",{"date":138,"type":21},"2026-01",{"date":140,"type":21},"2029-02",{"name":142,"class":43},"Nick Fancourt"]